GET DAILY SIGNALSWhy Is Carlsmed (CARL) Stock Down -3.24% Today?
Key Takeaways
- CARL shares were down about 3.24% in morning trading, slipping from a prior close of $16.05 to roughly $15.53.
- The decline comes as traders position ahead of the company's third-quarter 2026 earnings report, scheduled for release after the market close.
- Profit-taking is weighing on the stock after a sharp 10.5% rally in the previous session and a strong multi-week run.
- Broader pressure on rate-sensitive medical technology and growth names, tied to elevated Treasury yields, is adding to the selling.
- Analyst sentiment remains broadly positive, with a Strong Buy consensus and recently raised price targets.
- Traders are watching tonight's results and guidance for the next directional signal.
- For more context, explore Price Targets, Earnings, and Forecast pages for CARL.
- To see which automated strategies are currently outperforming, visit Trending AI Robots.
Opening Summary
CARL, the common stock of Carlsmed, Inc., a commercial-stage medical technology company that designs and markets AI-enabled personalized spine surgery solutions, is trading lower on Tuesday. Shares were down about 3.24% in morning trading, falling from a prior closing price of $16.05 to approximately $15.53. The move marks a pullback following a sharp rally in the prior session, as investors de-risk ahead of the company's third-quarter earnings report due after the closing bell.
Earnings Anticipation and Pre-Report De-Risking
The most immediate catalyst behind today's decline is the company's upcoming third-quarter 2026 financial results, scheduled for release after market close. Carlsmed previously confirmed it would report its results on November 10, 2026, followed by a management conference call. With a consensus estimate of roughly a $0.39 per-share loss on approximately $19.2 million in revenue, traders often trim positions ahead of a binary event like an earnings print, particularly for a volatile, early-stage growth company that has historically produced double-digit percentage swings around its reports.
Profit-Taking After a Sharp Rally
Today's retreat also reflects a natural bout of profit-taking. CARL surged more than 10% in the previous trading session, extending a stretch of strength that left the stock higher over the past week and month. After such a rapid advance, some investors choose to lock in gains before a catalyst that could swing the share price in either direction. This technical, sentiment-driven selling is compounding the pre-earnings caution.
Broader Market and Sector Pressure
The decline is occurring against a backdrop of pressure on rate-sensitive medical technology and growth equities. Elevated Treasury yields have weighed on high-multiple, unprofitable growth names, a category that includes CARL, which remains in a net-loss position even as revenue expands quickly. While company-specific catalysts have driven relative outperformance within the medtech group, the broader macro environment has kept a lid on speculative valuations and contributed to the defensive tone.
Market Context and Trading Activity
The stock's recent advance was accompanied by elevated trading activity, with the prior session's volume running above its recent daily average. Today's move appears more aligned with event-driven positioning than with any single negative headline, as the stock gives back a portion of its prior-session gains. From a technical standpoint, CARL remains well above its 50-day and 200-day moving averages after its multi-week uptrend, suggesting the current pullback is so far contained within a broader uptrend rather than a structural reversal.
What Comes Next for CARL
The primary near-term catalyst is tonight's third-quarter earnings report and management's guidance. Investors will focus on revenue growth, gross margin, adoption trends for the company's aprevo and corra product lines, and any update on cash runway. Analyst coverage remains constructive, with a Strong Buy consensus and several firms having reiterated Buy ratings and raised price targets in recent months. Risks include continued macro-driven pressure on growth valuations, execution against expansion plans, and the stock's inherent volatility around earnings events.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently among the strongest performers under prevailing market conditions. Tickeron offers hundreds of automated bots covering thousands of tickers, each differing by strategy, timeframe, performance metrics, and the symbols it trades. Exploring this section can help you discover quantitative approaches that align with your own investing style and objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CARL in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 27, 2026
CARL broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 11 similar instances where the stock broke above the upper band. In 10 of the 11 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 17 cases where CARL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for CARL entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CARL as a result. In 21 of 26 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CARL just turned positive on October 22, 2026. Looking at past instances where CARL's MACD turned positive, the stock continued to rise in 8 of 11 cases over the following month. The odds of a continued upward trend are 73%.
CARL moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CARL crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.
Following a +6.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CARL advanced for three days, in 59 of 72 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.706) is normal, around the industry mean (4.477). P/E Ratio (-6.214) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.596) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. CARL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CARL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement